Equine Facilitated CBT Group Therapy for Youth Anxiety
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03838835|
Recruitment Status : Terminated (COVID-19)
First Posted : February 12, 2019
Last Update Posted : September 30, 2020
|Condition or disease||Intervention/treatment||Phase|
|Anxiety||Behavioral: Augmented equine-facilitated CBT group program Behavioral: TAU is equine-facilitated group therapy Other: WLC||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||59 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Equine Facilitated Cognitive Behavioral Therapy (CBT) Group Therapy for Youth Anxiety|
|Actual Study Start Date :||November 15, 2018|
|Actual Primary Completion Date :||May 26, 2020|
|Actual Study Completion Date :||May 26, 2020|
|Experimental: Equine-facilitated group therapy||
Behavioral: TAU is equine-facilitated group therapy
TAU is equine-facilitated group therapy at GallopNYC, which consists of horseback riding and integrates strategies to support the development of cognitive, physical, emotional, and social skills.
|Experimental: Augmented equine-facilitated CBT group program||
Behavioral: Augmented equine-facilitated CBT group program
Consists of CBT strategies including 1) providing psychoeducation about anxiety, 2) teaching coping strategies when anxious,and 3) identifying and addressing dysfunctional thoughts that maintain anxiety.
|Wait List Control (WLC)||
WLC consists of youth who are not yet receiving any services at Gallop NYC.
- Anxiety, as measured by the SCARED [ Time Frame: Baseline to 10 Weeks ]41 item questionnaire scored on a 3-point Likert Scale ranging from "not true" to "very true." Items are summed, with higher scores indicating more anxiety symptoms (a cutoff of 25 indicates an anxiety disorder).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03838835
|United States, New York|
|NYU Langone Health|
|New York, New York, United States, 10016|
|Principal Investigator:||Kimberly Hoagwood, MD||New York Langone Medical Center|